World's Best Scientists 2026 revealed!
Yoram Bouhnik

Yoram Bouhnik

D-Index & Metrics

Medicine

D-Index
93
Citations
29837
World Ranking
10942
National Ranking
339

Yoram Bouhnik publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Yoram Bouhnik sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 477 publications — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Yoram Bouhnik D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Yoram Bouhnik sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Yoram Bouhnik is affiliated with Beaujon Hospital in France and has contributed extensively to medical research, particularly in gastroenterology and related fields. Their work spans a significant number of publications and focuses on several contemporary issues in inflammatory bowel disease treatment and management.

The main fields of study for Yoram Bouhnik include Medicine and Biochemistry, Genetics and Molecular Biology. Their research delves into subfields such as Genetics, Epidemiology, Immunology, Surgery, and Rheumatology.

Their primary research topics encompass:

  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Biosimilars and Bioanalytical Methods
  • Autoimmune and Inflammatory Disorders
  • Immunodeficiency and Autoimmune Disorders
  • Diagnosis and treatment of tuberculosis
  • Pharmaceutical studies and practices

Yoram Bouhnik has published recent papers focusing on treatment effectiveness and safety in chronic gastrointestinal conditions. Notable publications include:

  • The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor (2020) in Alimentary Pharmacology & Therapeutics
  • Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial (2023) in The Lancet. Gastroenterology & Hepatology
  • Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study (2021) in The Lancet. Gastroenterology & Hepatology
  • Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID (2020) in The American Journal of Gastroenterology
  • Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study (2020) in Alimentary Pharmacology & Therapeutics

The researcher frequently collaborates with several co-authors, including:

  • Laurent Peyrin-Biroulet
  • David Laharie
  • Aurélien Amiot
  • Lucine Vuitton
  • Stéphane Nancey

Publications by Bouhnik have appeared in a range of academic journals, with multiple entries in:

  • Journal of Crohn's and Colitis
  • Gastroenterology
  • Digestive and Liver Disease
  • Alimentary Pharmacology & Therapeutics
  • Inflammatory Bowel Diseases

Best Publications

  • Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

    Laurent Beaugerie;Nicole Brousse;Anne Marie Bouvier;Jean Frédéric Colombel

  • The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

    Gert Van Assche;Axel Dignass;Walter Reinisch;C. Janneke van der Woude

  • Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines

    J. Panes;Y. Bouhnik;W. Reinisch;J. Stoker

  • Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

    Edouard Louis;Jean–Yves Mary;Gwenola Vernier–Massouille;Jean–Charles Grimaud

  • Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial

    David Laharie;Arnaud Bourreille;Julien Branche;Matthieu Allez

  • The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study

    Yoram Bouhnik;Laurent Raskine;Guy Simoneau;Eric Vicaut

  • Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy

    Hongxiang Liu;Agnes Ruskon-Fourmestraux;Anne Lavergne-Slove;Hongtao Ye

  • Short-Chain Fructo-Oligosaccharide Administration Dose-Dependently Increases Fecal Bifidobacteria in Healthy Humans

    Yoram Bouhnik;Kouroche Vahedi;Lotfi Achour;Alain Attar

  • A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine.

    Marc Lémann;Jean-Yves Mary;Jean-Frédéric Colombel;Bernard Duclos

  • Presentation and Long-Term Follow-up of Refractory Celiac Disease: Comparison of Type I With Type II

    Georgia Malamut;Pauline Afchain;Virginie Verkarre;Thierry Lecomte

  • Administration of Transgalacto-Oligosaccharides Increases Fecal Bifidobacteria and Modifies Colonic Fermentation Metabolism in Healthy Humans

    Yoram Bouhnik;Bernard Flourié;Laurence D'Agay-Abensour;Philippe Pochart

  • Abnormal Intestinal Intraepithelial Lymphocytes in Refractory Sprue

    Christophe Cellier;Natacha Patey;Laurent Mauvieux;Bana Jabri

  • Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease

    Tamara Matysiak-Budnik;Ivan Cruz Moura;Ivan Cruz Moura;Michelle Arcos-Fajardo;Michelle Arcos-Fajardo;Corinne Lebreton;Corinne Lebreton

  • Safety and Efficacy of Antigen-Specific Regulatory T-Cell Therapy for Patients With Refractory Crohn's Disease

    Pierre Desreumaux;Arnaud Foussat;Matthieu Allez;Laurent Beaugerie

  • Risk Factors for Intra-Abdominal Septic Complications After a First Ileocecal Resection for Crohn’s Disease: A Multivariate Analysis in 161 Consecutive Patients

    Arnaud Alves;Yves Panis;Yoram Bouhnik;Marc Pocard

  • Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED–ECCO consensus

    A. Bourreille;A. Ignjatovic;L. Aabakken;E. V. Loftus

  • Identification of Restricted Subsets of Mature microRNA Abnormally Expressed in Inactive Colonic Mucosa of Patients with Inflammatory Bowel Disease

    Magali Fasseu;Xavier Tréton;Xavier Tréton;Cécile Guichard;Cécile Guichard;Eric Pedruzzi;Eric Pedruzzi

  • Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

    Geert D'Haens;Severine Vermeire;Guy Lambrecht;Filip Baert

  • Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease.

    Kouroche Vahedi;Françoise Mascart;Jean Yves Mary;Jean Eric Laberenne

  • Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial.

    Alain Attar;Bernard Flourié;Jean–Claude Rambaud;Claire Franchisseur

Frequent Co-Authors

Matthieu Allez
Matthieu Allez Université Paris Cité
Jean-Frederic Colombel
Jean-Frederic Colombel Icahn School of Medicine at Mount Sinai
Yves Panis
Yves Panis Université Paris Cité
Laurent Peyrin-Biroulet
Laurent Peyrin-Biroulet University of Lorraine
Marc Lémann
Marc Lémann Université Paris Cité
Xavier Hébuterne
Xavier Hébuterne Université Côte d'Azur
Edouard Louis
Edouard Louis University of Liège
Franck Carbonnel
Franck Carbonnel University of Paris-Saclay

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring options beyond traditional Medicine degrees can open doors to rewarding careers in healthcare. Many students look for flexible, accessible programs that allow them to gain vital skills online. For example, if you’re interested in administrative roles, consider medical billing and coding schools that accept fafsa. This path can help you enter the healthcare field quickly with support from federal aid.

Nursing also offers multiple online pathways. You might wonder, do you have to take a teas test for lpn? Many reputable LPN programs waive entrance exams, making it easier to start your nursing education. For those aiming at management, an healthcare administration accelerated degree can fast-track you to leadership positions.

Already a registered nurse? Advancing to a nurse practitioner role is streamlined with rn to fnp bridge programs. These online bridge degrees help RNs become Family Nurse Practitioners efficiently while balancing work and study.

Best Scientists Citing Yoram Bouhnik

Trending Scientists

Recently Published Articles